대한화장품학회지. 2022 Mar; 48 (1): 8381534. doi: 10.15230/SCSK.2022.48.1.77
레틴알 안정화를 위한 사이클로덱스트린-리포좀에 관한 연구
Study on Stabilization of Retinaldehyde using Drug-in-Cyclodextrinin-Liposome (DCL) for Skin Wrinkle Improvement
하지훈
,
최형
,
홍인기
,
한상근
,
빈범호
-
-
원문보기
-
조회
상세조회 325건
-
-
Abstract
Retinaldehyde (RA), vitamin A derivative, is an intermediate between retinol and retinoic acid and has an excellent wrinkle improving effect. In this study, Drug-in-cyclodextrin-in-liposome (DCL) was used to enhance the stability and skin penetration of RA. The complex of RA and hydroxypropyl-beta-cyclodextrin (HP-β-CD) was prepared by the freeze-drying method, and the presence or absence of inclusion of retinal was confirmed by UV-Vis spectrometer, FT-IR and SEM images. RA was captured in HP-β-CD about 95.6% on 1 : 15 (w/w). The retinal-HP-β-CD complex was encapsulated in liposomes using a homomixer and microfluidizer, with an average particle size of 215 ± 4.2 nm and a zeta potential of -31.2 ± 0.5 mv. In the evaluation of the degradation stability of RA, degradation rate of RA-HP-β-CD-liposomes in water was 1.8% higher than RA-liposome (5.8%), RA-HP-β-CD complex (9.7%) and RA alone (37.6%). RA cream (0.05% RA) including RA-HP-β-CD-liposomes was prepared for clinical test with wrinkle-improving efficacy and skin dermis denseness evaluated for 2 or 4 weeks. RA cream showed a significant wrinkle improving effect without skin irritation. In conclusion, it was confirmed that the double stabilization technology using the DCL system contribu tes to the effect of improving skin wrinkles by increasing the stabilization of retinal.
-
Keywords
-
References
more
references
1. S. Gibbs, C. Backendorf, and M. Ponec, Regulation of keratinocyte proliferation and differentiation by all-transretinoic acid, 9-cis-retinoic acid and 1, 25-dihydroxy vitamin D3, Arch. Dermatol. Res., 288(12), 729 (1996).
2. S. Mukherjee, A. Date, V. Patravale, H. Christian Korting, A. Roeder, and G. Weindl, Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety, Clin. Interv. Aging, 1(4), 327 (2006).
3. G. Siegenthaler, J. H. Saurat and M. Ponec, Retinol and retinal metabolism. Relationship to the state of differentiation of cultured human keratinocytes, Biochem J., 268(2), 371 (1990).
4. J. H Saurat, L. Didierjean, E. Masgrau, P.A. Piletta, S. Jaconi, D. Chatellard-Gruaz, D. Gumowski, I. Masouy, D. Salomon, G. Siegenthaler, Topical retinaldehyde on human skin: biologic effects and tolerance, J. Invest. Dermatol., 103(6), 770 (1994).
5. J. Peter, J. Stanek and S. Gupta, Retinaldehyde cyclodextrin complex for topical skin therapy, Glob. Dermatol., 2(6), 232 (2015).
6. T. Loftsson and M. E. Brewster, Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes, J. Pharm. Pharmacol., 63(9), 1119 (2011).
7. J. Chen, W. L. Lu, W. Gu, S. S. Lu, Z. P. Chen, B. C. Cai, and X. X. Yang, Drug-in-cyclodextrin-in liposomes: a promising delivery system for hydrophobic drugs, Expert. Opin. Drug. Deliv., 11(4), 565 (2014).
8. B. McCormack and G. Gregoriadis, Drugs-in-cyclodextrinsin liposomes: a novel concept in drug delivery, Int. J. Pharm., 112(3), 249 (1994).
9. M. C. Lira, M. S. Ferraz, D. G. da Silva, M. E. Cortes, K. I . Teixeira, N. P. Caetano, and N. S. Santos-Magalhes, Inclusion complex of usnic acid with β-cyclodextrin: characterization and nanoencapsulation into liposomes, J. Incl. Phenom. Macrocycl. Chem., 64, 215 (2009).